

Corbus Pharmaceuticals reports positive Phase 1b trial results for obesity drug CRB-913, demonstrating significant 12-week weight loss.
You can purchase shares of Corbus Pharmaceuticals (NASDAQ:CRBP) through any online brokerage.
Other companies in Corbus Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Corbus Pharmaceuticals has a consensus price target of $42.55.
The stock price for Corbus Pharmaceuticals (NASDAQ: CRBP) is $4.15 last updated October 28, 2026 at 12:05 PM EDT.
There are no upcoming dividends for Corbus Pharmaceuticals.
Corbus Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Corbus Pharmaceuticals.
Corbus Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological...